Quick Answer
The EGRIFTA SV label does not say tesamorelin causes cancer. It does say not to treat patients with active malignancy, because tesamorelin stimulates endogenous growth hormone and GH is a known growth factor. It also recommends careful evaluation in people with a history of malignancy.
That is the right framing: tesamorelin has a strong clinical body-composition case, and it also has real label boundaries around malignancy and IGF-1.
Explore the AminoRank tesamorelin profileReview linked studies, category details, and vendor availability for tesamorelin.View tesamorelin profileWhy Cancer Comes Up With Tesamorelin
Cancer questions come up because tesamorelin works through the growth-hormone axis. It stimulates GH production and increases IGF-1. Growth signals are powerful, and powerful biology deserves clear boundaries.
This does not mean tesamorelin is a cancer-causing peptide. It means the label takes active malignancy seriously and treats GH/IGF-1 biology with appropriate respect.
What The Label Says
DailyMed lists active malignancy as a contraindication. It also says preexisting malignancy should be inactive and treatment complete before starting EGRIFTA SV. For people with a history of treated and stable malignancy, the label calls for careful evaluation of benefit versus risk.
| Label topic | Practical meaning |
|---|---|
| Active malignancy | Contraindicated. |
| History of malignancy | Benefit and risk should be carefully evaluated. |
| GH as growth factor | The warning is tied to tesamorelin's GH-stimulating mechanism. |
| IGF-1 | Persistent elevations are a monitoring issue. |
| Mutagenicity | No potential mutagenicity was revealed in listed tests. |
What The Label Does Not Say
The label does not say that tesamorelin has been proven to cause cancer. It also does not erase the clinical benefits seen in visceral-fat studies. A serious label can contain both: meaningful benefit and meaningful safety boundaries.
This is why the best answer to "does tesamorelin cause cancer?" is not a dramatic yes or no. The better answer is that active malignancy is contraindicated, GH/IGF-1 signaling is monitored, and nonclinical testing did not reveal mutagenicity in the listed assays.
IGF-1 Monitoring Matters
Tesamorelin raises IGF-1. DailyMed says the effects of prolonged IGF-1 elevations are unknown and recommends IGF-1 monitoring. Persistent elevation may lead to discontinuation in label context, especially if the efficacy response is not robust.
This is not a reason to be anti-tesamorelin. It is a reason to treat tesamorelin like a real clinical peptide instead of a casual supplement.
What The Safety Studies Add
The long-term safety study reported tesamorelin was generally well tolerated over 52 weeks and that glucose changes were not clinically significant in that study. The trial also showed sustained visceral-fat and triglyceride benefits during continued treatment.
That broader context matters. Tesamorelin's safety conversation is not just a warning section. It includes controlled studies, label monitoring, and a benefit profile that is unusually strong for visceral abdominal fat.
Product Quality Does Not Replace Screening
Safety screening and product quality are separate issues. A clean-looking vendor listing does not answer malignancy-history, IGF-1, or glucose questions. It only helps answer whether the research product is clearly documented.
Tesamorelin Vendors With Documentation Signals
View all Tesamorelin vendors| Vendor | Country | COAs | Rating | Reviews | Notes | Website |
|---|---|---|---|---|---|---|
| LA Peptides | USA | Yes | 5.0 | 1 | Verified listing | Buy |
| NextGenPeps | USA | Yes | 5.0 | 1 | Verified listing | Buy |
| Alpha Peptides | USA | Yes | 0.0 | 0 | Verified listing | Buy |
| Ascension Peptides | USA | Yes | 0.0 | 0 | Verified listing | Buy |
| BioCollex | USA | Yes | 0.0 | 0 | Verified listing | Buy |
| Coastal Peptides | USA | Yes | 0.0 | 0 | Verified listing | Buy |
FAQ
Is tesamorelin carcinogenic?
The label says lifetime rodent carcinogenicity studies were not conducted, but no potential mutagenicity was revealed in listed tests.
Why is active cancer contraindicated?
Because tesamorelin stimulates GH production, and GH is a known growth factor.
Does IGF-1 mean tesamorelin is dangerous?
No. IGF-1 is part of tesamorelin's pharmacology, but prolonged elevations are a monitoring issue.
Is tesamorelin still a strong peptide despite this warning?
Yes. The warning defines responsible boundaries; it does not erase the visceral-fat evidence.